Pfizer's Torisel misses second-line RCC endpoint

Pfizer Inc. (NYSE:PFE) said IV Torisel temsirolimus missed the primary endpoint of progression-free survival (PFS) vs. oral Nexavar sorafenib in the Phase III INTORSECT trial to treat advanced renal cell carcinoma in patients who failed first-line treatment with Sutent sunitinib. Additionally, Pfizer said data for the secondary overall survival (OS) endpoint showed significance favoring Nexavar. The open-label, international trial enrolled 512 patients. ...